Danish drugmaker Novo Nordisk has reported sales in line with expectations at 108 billion Danish krone ($15.98 billion) for the first six months in 2023, up 30% 10 August 2023
The competition to address two areas of huge unmet medical need is heating up, and Eli Lilly (NYSE: LLY) has a chance of being the leader in both. 8 August 2023
More positive data for Eli Lilly’s weight loss candidate tirzepatide will boost interest in the product, as the US regulator warns of supply shortages at certai 28 July 2023
Obesity is one of the most urgent health challenges of our time.With more than half the global population estimated to be either overweight or living with obesi 24 July 2023
The safety monitoring committee of the European Medicines Agency is to investigate a potential connection between the use of certain Novo Nordisk products and s 11 July 2023
US pharma major Eli Lilly is to acquire Sigilon Therapeutics, a biopharma company seeking to develop functional cures for patients with a range of acute and chr 29 June 2023
Mounjaro (tirzepatide) has not been recommended in draft guidance issued by the National Institute for Health and Care Excellence (NICE) on Tuesday for treating 27 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.